Alumis ALMS
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Alumis (ALMS) Business Model and Operations Summary
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.
Key Insights
Alumis (ALMS) Core Market Data and Business Metrics
Latest Closing Price
$7.24Market Cap
$382.62 MillionPrice-Earnings Ratio
-0.70Total Outstanding Shares
47.22 Million SharesTotal Employees
170Dividend
No dividendIPO Date
June 28, 2024SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
280 East Grand Avenue, South San Francisco, CA, 94080
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow | $123.50 Million |
| Net Cash Flow From Investing Activities | $-113.79 Million |
| Net Cash Flow From Financing Activities | $492.37 Million |
| Net Cash Flow From Operating Activities | $-255.08 Million |
| Net Cash Flow From Financing Activities, Continuing | $492.37 Million |
| Net Cash Flow, Continuing | $123.50 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Diluted Average Shares | $28.34 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
| Income Tax Expense/Benefit | $0 |
| Net Income/Loss Attributable To Parent | $-294.23 Million |
| Preferred Stock Dividends And Other Adjustments | $0 |
| Diluted Earnings Per Share | $-10.38 |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss | $38,000 |
| Comprehensive Income/Loss | $-294.19 Million |
| Comprehensive Income/Loss Attributable To Parent | $-294.19 Million |
| Other Comprehensive Income/Loss Attributable To Parent | $38,000 |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Equity Attributable To Parent | $260.10 Million |
| Current Assets | $306.19 Million |
| Fixed Assets | $20.97 Million |
| Other Non-current Assets | $13.84 Million |
| Noncurrent Liabilities | $29.98 Million |
| Cash | $288.30 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||